{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2010"],"condition":["Pain","Constipation","Moderate to severe chronic non-cancer or cancer pain with opioid induced constipation"],"disease":["Moderate To Severe Chronic Non-cancer Or Cancer Pain With Opioid Induced Constipation","Pain","Constipation"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2079187"],"location":["Romania","Czechia","United States","United Kingdom","Switzerland","Austria","Netherlands","Belgium","Finland","Denmark","Poland","Israel","France","Australia","Germany"],"study_start_month":["1"],"keyword":["8 mg Naloxone Hydrochloride Prolonged Release Tablets","Hydromorphone","Naloxone","2 mg Naloxone Hydrochloride Prolonged Release Tablets","Palladone SR capsules","Confirmatory","32 mg Naloxone Hydrochloride Prolonged Release Tablets"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain","description":"The purpose of this study is to establish an optimal hydromorphone - naloxone ratio with an improved bowel function for constipated pain patients.","dates":{"creation":"2010-01-15"},"accession":"2079187","cross_references":{"ClinicalTrials___gov":["NCT00992576"],"EU Clinical Trials Register":["2008-005315-18","2008-005312-18"]}}